Marshall Wace, LLP Bridge Bio Pharma, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 833,236 shares of BBIO stock, worth $23.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

833,236

Previous 30,849 2601.01%

Holding current value

$23.8 Million

Previous $781,000 2616.26%

% of portfolio

0.03%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.91 - $31.3 $19.2 Million - $25.1 Million	802,387 Added 2601.01%	833,236 $21.2 Million
Q2 2024 Aug 14, 2024	BUY	$23.0 - $31.04 $709,527 - $957,552	30,849 New	30,849 $781,000
Q4 2023 Feb 14, 2024	SELL	$24.02 - $43.89 $3 Million - $5.49 Million	-125,019 Reduced 76.74%	37,897 $1.53 Million
Q3 2023 Nov 14, 2023	BUY	$16.89 - $35.01 $2.75 Million - $5.7 Million	162,916 New	162,916 $4.3 Million
Q1 2023 May 15, 2023	BUY	$7.17 - $18.55 $7.78 Million - $20.1 Million	1,084,595 New	1,084,595 $18 Million
Q3 2022 Nov 14, 2022	BUY	$7.94 - $12.36 $565,685 - $880,588	71,245 New	71,245 $708,000
Q1 2022 May 16, 2022	SELL	$7.34 - $17.16 $2.13 Million - $4.98 Million	-290,362 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.38 - $53.41 $3.13 Million - $14.7 Million	274,843 Added 1771.01%	290,362 $4.84 Million
Q3 2021 Nov 15, 2021	BUY	$46.87 - $64.24 $727,375 - $996,940	15,519 New	15,519 $727,000
Q2 2021 Aug 13, 2021	SELL	$46.47 - $63.93 $3.53 Million - $4.86 Million	-75,995 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$55.47 - $72.35 $4.22 Million - $5.5 Million	75,995 New	75,995 $4.68 Million

Others Institutions Holding BBIO

# of Institutions

290

Shares Held

170M

Call Options Held

10.4M

Put Options Held

2.37M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $4.23B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Bridge Bio Pharma, Inc. Transaction History